Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT07144137

A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA) — Recruiting • NCT07144137.

📅 13 Jul 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT07144137
Start
2025-07-30
Completion
2027-03-31
ClinicaliQ Trial Snapshot
  • A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA) — Recruiting • NCT07144137.
  • Study tracking how geographic atrophy (vision loss from AMD) progresses in older adults, examining structural changes and links to genetics or lifestyle factors.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

This is a non-interventional, observational study to provide insights into the short-term progression of GA secondary to AMD in participants aged ≥55 years. This is a multi-center, non-interventional, observational study which aims to identify participants who have progressive GA to allow quantification of structural and functional parameters that characterize the progression of GA, and to investigate whether these correlate with genetic or lifestyle factors. Conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration Lead Sponsor: Complement Therapeutics Planned Enrollment: 75 participants

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn